TY  - JOUR
T1  - Extranodal diffuse large B-cell lymphoma: Experience from a tertiary care oncology center in South India
A1  - K. Lakshmaiah
A1  - K. Lokesh
A1  - Vishwanath Sathyanarayanan
A1  - C. Premalatha
A1  - Clementina Rao
A1  - T Suresh
A1  - K. Babu
A1  - D. Lokanatha
A1  - Linu Jacob
A1  - Suresh Babu
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2014
VL  - 3
IS  - 4
DO  - 10.4103/2278-0513.134468
SP  - 276
EP  - 280
N2  - Aims: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin′s lymphoma (NHL) with frequent extra nodal (EN) presentation. The overall occurrence of lymphomas has been increasing; however, those of EN-NHL have been increasing much more rapidly. There is limited data found on EN-DLBCL in the Indian population and hence we carried out this retrospective observational study of primary EN-DLBCL at our center in Southern India. Materials and Methods: A total of 90 consecutive cases diagnosed as EN-DLBCL (according to the standard criteria) by tissue biopsy confirmed by immunohistochemistry between 2007 and 2011 were included. Staging workup including computed tomography of neck, thorax and abdomen and pelvis, bone marrow aspiration and biopsy was done and International Prognostic Index (IPI) calculated. Staging was according to Cotswold′s modification of Ann Arbor. The actuarial survival analysis was performed by Kaplan-Meier. Data were analyzed using the SPSS (version 16) statistical software. Results: The median age in this study was 49 years (18-88) with results showing EN-DLBCL to be 1.36 times more common in males. Advanced stages were seen in 15 subjects (16.6%) and bulky disease in 13 subjects (14.4%). CD20 was positive in 89 (98.8%) while 32 had high serum lactate dehydrogenase. According to the IPI most were low-risk-56 (66.6%). Overall response rate for the various combination chemotherapies was 85.7% with complete response in 62.3%. The overall survival range spanned from 2 to 123 months. Univariate analysis showed only bulky disease was associated with inferior survival. Conclusions: EN-DLBCL was present at an early age compared to nodal DLBCL, present more often in early stage and low IPI score. Chemoimmunotherapy with radiotherapy to the EN or bulky site is the standard treatment at present.
UR  - https://ccij-online.org/article/extranodal-diffuse-large-b-cell-lymphoma:-experience-from-a-tertiary-care-oncology-center-in-south-india-225
ER  -